Access the Curi Engine
By integrating biology and engineering in the preclinical pipeline, Curi Bio can help improve the discovery, safety, and efficacy of your studies.
Curi Bio offers a suite of services utilizing our integrated platforms of human iPSC-derived cells, tissue-specific biosystems, and AI-enabled phenotypic screening. Curi Bio’s team of experts can help customize and execute studies to meet your desired endpoints.
Examples of Services Curi Bio Offers
Project Scoping
Hybrid Model (FFS + FTE)
Fee for Service (FFS) contracts are typically utilized for more concise “off the shelf” assays and work packages where there is little to no “risk” or deviation from the proposed work package. For larger and more amorphous, multiple milestone projects, such as novel disease model generation and phenotyping, etc., we recommend (and may require) using a Full Time Equivalent (FTE) model of contracting or hybrid (FFS + FTE).
The FTE model provides several benefits. It allows us to flexibly perform and accurately account for Sponsor-approved work falling outside the scope of an original Work Package (without the need for revising contracts). We often see projects go outside the scope of planned work package estimates due to the data leading us one way or the other. Examples would include additional weeks of 3D engineered muscle tissue (EMT) culture, additional stress induction, etc. to exacerbate phenotypes, repeat studies, expanded compound tests, and other requests.
Cost for FTE vs. FFS work packages are calculated in essentially the same way (by expected # of hours for various tasks + reagents + instrument time, etc). Curi Bio may be able to offer a cost/risk share partnership which would reduce the total upfront project costs in exchange for reasonable clinical success milestones. We see these partnerships as an opportunity to grow together, working towards a common goal of getting medicines to patients faster and reducing animal testing.
We are always looking forward to further collaboration!
Please contact Curi Bio’s Services team with inquiries.
Disease Model Development
Curi Bio has a repository of iPSC’s for disease modeling and proprietary technologies for differentiating these cells into myoblasts and cardiomyocytes. Curi Bio has developed in vitro 3D disease models for multiple disease phenotypes. In addition, Curi Bio has the capability of generating new gene-edited iPSC models in house.
Examples of Disease Model Services Curi Bio Offers
Design and Manufacture of Isogenic Gene-edited Diseased/Wild Type (WT) Pairs
3D Engineered Heart Tissue (EHT) or Engineered Skeletal Muscle Tissue (EMT) Using Proprietary WT/Duchenne Muscular Dystrophy (DMD) Isogenic Pairs
Differentiation of Your iPSC Lines Into Myoblasts and Cardiomyocytes
iPSC Reprogramming
Therapeutic Potency Testing
Histological analysis of 3D EMT cross sections shows distribution of myosin positive myotubes in control (WT) but not DMD tissues.
Assay Development
Curi Bio has deep expertise in developing rigorous and novel assays. Curi Bio’s team of expert scientists and engineers have the experience and equipment to develop personalized assays and protocols to meet your custom needs.
Examples of Assay Development Services Curi Bio Offers
Custom Differentiation Protocols
Qualified Protein Quantification
Custom 3D-engineered Tissues
Custom Drug Profiling Assays
Custom Imaging Assays
Discovery
Curi Bio's team of stem cell, cardiac, and muscle experts joins forces with our engineers and software developers to help get your discovery project off the ground. Curi Bio offers both FTE-based or project-based service options.
Talk to Our Services Team Today to Learn How Curi Bio Can Help
Cell Repositories
Curi Bio’s iPSC Repositories Available for Services
Custom Panel of Different Gender and Ethnicities
Disease Model Pairs
Patient-derived iPSC-lines
Isogenic DMD/WT Myoblasts
Isogenic DMD/WT Cardiomyocytes